A Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Mavorixafor (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors X4 Pharmaceuticals
- 30 Nov 2022 Status changed from completed to discontinued.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 28 Jan 2021 Results published in the Investigational New Drugs.